Back to top

Cynosure Appoints Stephen J. Webber to CFO & Other Roles

Read MoreHide Full Article

Marketer of aesthetic treatment systems, Cynosure, Inc. announced that it has appointed Stephen J. Webber as Executive Vice President. The appointment will be effective from Oct 10, 2016. Webber would also take additional responsibilities of Chief Financial Officer and Chief Accounting Officer. However, the additional responsibilities would be effective upon the filing of Cynosure's quarterly report in November for the three-month period ending Sep 30, 2016.  

Webber would succeed Timothy W. Baker, who announced his planned retirement from Cynosure in May to pursue philanthropic interests. However, Baker would continue to serve in a consulting role during a transition period expected to continue till Mar 2017.

Webber has a solid track record of operational and cost improvement, value creation and asset optimization. From 2012 to 2015, Webber was Senior Vice President of Finance and Operations at Dell EMC . Before that, he spent four years at Deloitte & Touche LLP in Boston in the audit practice with a focus on public companies.

Cynosure develops, manufactures, and markets aesthetic treatment systems. The systems aid plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures. The company also markets radiofrequency energy-sourced medical devices for precision surgical applications.

The company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the U.S., Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.

Zacks Rank and Key Picks

Currently, Cynosure has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector include GW Pharmaceuticals plc (GWPH - Free Report) and Quidel Corp. (QDEL - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

GW Pharmaceuticals PLC (GWPH) - free report >>

Quidel Corporation (QDEL) - free report >>

More from Zacks Analyst Blog

You May Like